Staging biomarkers in preclinical autosomal dominant Alzheimer’s disease by estimated years to symptom onset

Staging preclinical Alzheimer disease (AD) by the expected years to symptom onset (EYO) in autosomal dominant AD (ADAD) through biomarker correlations is important.